Sandra Swain
Sandra Swain
Verified email at
Cited by
Cited by
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
EH Romond, EA Perez, J Bryant, VJ Suman, CE Geyer Jr, NE Davidson, ...
New England journal of medicine 353 (16), 1673-1684, 2005
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
P Cortazar, L Zhang, M Untch, K Mehta, JP Costantino, N Wolmark, ...
The Lancet 384 (9938), 164-172, 2014
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer
J Baselga, J Cortés, SB Kim, SA Im, R Hegg, YH Im, L Roman, JL Pedrini, ...
New England Journal of Medicine 366 (2), 109-119, 2012
Congestive heart failure in patients treated with doxorubicin A retrospective analysis of three trials
SM Swain, FS Whaley, MS Ewer
Cancer: Interdisciplinary International Journal of the American Cancer …, 2003
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer
SM Swain, J Baselga, SB Kim, J Ro, V Semiglazov, M Campone, ...
New England journal of medicine 372 (8), 724-734, 2015
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials
Early Breast Cancer Trialists' Collaborative Group
The Lancet 379 (9814), 432-444, 2012
Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women …
DLW Kwong, P McGale, C Taylor, C Correa, D Cutter, F Duane, M Ewertz, ...
The Lancet, 2014
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3
J Baselga, SM Swain
Nature Reviews Cancer 9 (7), 463-475, 2009
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo …
SM Swain, SB Kim, J Cortés, J Ro, V Semiglazov, M Campone, E Ciruelos, ...
The lancet oncology 14 (6), 461-471, 2013
Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2–positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG …
EA Perez, EH Romond, VJ Suman, JH Jeong, G Sledge, CE Geyer Jr, ...
Journal of clinical oncology 32 (33), 3744-3752, 2014
Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in …
E Tan-Chiu, G Yothers, E Romond, CE Geyer Jr, M Ewer, D Keefe, ...
Journal of Clinical Oncology 23 (31), 7811-7819, 2005
Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials
B Asselain, W Barlow, J Bartlett, J Bergh, E Bergsten-Nordström, J Bliss, ...
The Lancet Oncology 19 (1), 27-39, 2018
3rd ESO–ESMO international consensus guidelines for advanced breast cancer (ABC 3)
F Cardoso, A Costa, E Senkus, M Aapro, F André, CH Barrios, J Bergh, ...
The Breast 31, 244-259, 2017
Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS
IL Wapnir, JJ Dignam, B Fisher, EP Mamounas, SJ Anderson, TB Julian, ...
Journal of the National Cancer Institute 103 (6), 478-488, 2011
Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.
SM Swain, FS Whaley, MC Gerber, S Weisberg, M York, D Spicer, ...
Journal of clinical oncology 15 (4), 1318-1332, 1997
Estimating the risks of breast cancer radiotherapy: evidence from modern radiation doses to the lungs and heart and from previous randomized trials
C Taylor, C Correa, FK Duane, MC Aznar, SJ Anderson, J Bergh, ...
Journal of Clinical Oncology 35 (15), 1641-1649, 2017
Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells
KA West, J Brognard, AS Clark, IR Linnoila, X Yang, SM Swain, C Harris, ...
The Journal of clinical investigation 111 (1), 81-90, 2003
Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer
SB Wedam, JA Low, SX Yang, CK Chow, P Choyke, D Danforth, ...
Journal of Clinical Oncology 24 (5), 769-777, 2006
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials
Early Breast Cancer Trialists' Collaborative Group
The Lancet 386 (10001), 1353-1361, 2015
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
M Martin, FA Holmes, B Ejlertsen, S Delaloge, B Moy, H Iwata, ...
The lancet oncology 18 (12), 1688-1700, 2017
The system can't perform the operation now. Try again later.
Articles 1–20